Emergency Department Evaluation of Suspected Arthritis in Young Adults

Clinical Assessment

Joint swelling accompanied by pain or stiffness defines true arthritis and helps differentiate it from cellulitis, bursitis, or soft‑tissue infection – American College of Rheumatology (ACR) recommendation. 1
Perform the “squeeze test” on metacarpophalangeal and metatarsophalangeal joints to detect small‑joint involvement – ACR guidance. 1
Morning stiffness lasting longer than 30 minutes and counting the number of swollen and tender joints are key features of inflammatory arthritis – ACR guidance. 1

Red‑Flag Management (Septic Arthritis)

If septic arthritis is suspected (typically mono‑articular presentation with fever, erythema, warmth, and severe pain), joint aspiration must be performed immediately – ACR emergency protocol. 2
Aspirated fluid should be sent for Gram stain, bacterial culture, cell‑count with differential, and crystal analysis – American College of Radiology (ACR) imaging guideline. 3

Baseline Laboratory Evaluation

Order a complete blood count to identify infection or systemic inflammatory disease – ACR recommendation. 1
Measure ESR and CRP; elevated levels predict a higher risk of persistent or erosive disease – ACR recommendation. 2
Test rheumatoid factor (RF) and anti‑CCP antibodies; a positive anti‑CCP result predicts erosive disease even when RF is negative – ACR recommendation. 2
Screen for antinuclear antibodies (ANA) to evaluate for connective‑tissue disease – ACR recommendation. 1
Perform urinalysis and baseline transaminases before any potential disease‑modifying antirheumatic drug (DMARD) therapy – ACR recommendation. 1

Imaging Strategy

Clinical examination remains the primary method for detecting arthritis – ACR recommendation. 1
Obtain plain radiographs of the affected joints as a baseline to identify early erosive changes – ACR recommendation. 1
Use power‑Doppler ultrasound when the physical exam is equivocal to confirm synovitis, detect effusion, and assess for lymphadenopathy – ACR recommendation. 2
Reserve MRI for cases where ultrasound is unavailable or the diagnosis remains doubtful – ACR recommendation. 1

Emergency Department Symptomatic Management

Administer NSAIDs (e.g., naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily) for 4–6 weeks, using the lowest effective dose after assessing gastrointestinal, renal, and cardiovascular risk – ACR guideline. 2
If NSAIDs are ineffective or contraindicated, give a short course of oral prednisone (10–20 mg daily for 2–4 weeks), limiting total glucocorticoid exposure to less than 6 months – ACR guideline. 2
Consider intra‑articular glucocorticoid injection for rapid relief of mono‑articular inflammation – ACR guideline. 2
Avoid chronic low‑dose glucocorticoid therapy, as it is strongly discouraged – ACR guideline. 2

Referral and Early Disease‑Modifying Therapy

Arrange rheumatology follow‑up within 6 weeks of symptom onset; do not wait for additional serologic results – ACR recommendation. 1
Patients identified as high risk for persistent arthritis should start methotrexate within 3 months to improve long‑term outcomes – ACR recommendation. 2
Early initiation of disease‑modifying therapy prevents joint damage and improves morbidity; multiple studies show better outcomes when treatment begins promptly – ACR evidence base. 1

Risk Stratification for Persistent/Erosive Disease

Higher numbers of swollen and tender joints, elevated ESR/CRP, and positive RF or anti‑CCP antibodies are associated with increased risk of persistent or erosive arthritis – ACR risk assessment. 2

Urgent Referral and Early Management of Undifferentiated Inflammatory Arthritis

Referral Timing

Patients with any joint swelling accompanied by pain or stiffness should be referred to a rheumatology specialist within 6 weeks of symptom onset to optimise outcomes. 4

Clinical Assessment Criteria

A three‑week history of unilateral hand swelling with positive antinuclear antibody (ANA) and negative rheumatoid factor meets criteria for early undifferentiated inflammatory arthritis and warrants prompt specialist evaluation. [4][5]

Serologic Evaluation

Negative rheumatoid factor does not exclude early rheumatoid arthritis or other inflammatory arthritides; seronegative disease is common in the initial phase. [6][7]
Anti‑cyclic citrullinated peptide (anti‑CCP) testing should be performed even when rheumatoid factor is negative, as anti‑CCP positivity predicts erosive disease. 6
Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) are essential acute‑phase reactants for gauging inflammatory activity and forecasting persistent or erosive arthritis. [4][7]

Imaging Recommendations

Power‑Doppler ultrasound of the affected hand (and axillary region, if symptomatic) is advised to confirm synovitis, detect joint effusion, and evaluate for lymphadenopathy. [8][7]
Baseline hand radiographs should be obtained to identify early erosive changes. [7][9]

Initial Symptomatic Pharmacotherapy

Non‑steroidal anti‑inflammatory drugs (e.g., naproxen 500 mg BID or meloxicam 7.5–15 mg daily) are recommended for 4–6 weeks, using the lowest effective dose and shortest duration necessary. [4][10]
If NSAIDs are ineffective or contraindicated, a short course of low‑dose oral prednisone (10–20 mg daily for 2–4 weeks) may be used, limiting systemic glucocorticoid exposure to less than 6 months. [4][11]

Critical Pitfalls to Avoid

Do not postpone rheumatology referral while awaiting additional serologic results; the 6‑week window is critical for early disease‑modifying therapy. [4][8]
Do not dismiss the possibility of inflammatory arthritis solely because rheumatoid factor is negative; early disease‑modifying antirheumatic drug (DMARD) initiation within 3 months improves prognosis. [4][12]
Do not attribute the presentation exclusively to non‑inflammatory causes (e.g., lymphedema) without rheumatologic assessment, especially in the presence of ANA positivity. 13

Risk Stratification for Persistent/Erosive Disease

Assessment should include the count of swollen and tender joints, levels of ESR/CRP, and imaging findings (ultrasound and radiographs) to identify patients at higher risk of chronic, erosive arthritis. [7][10]14

DMARD Initiation Strategy

In patients identified as at‑risk for persistent arthritis, methotrexate should be started as the anchor DMARD (unless contraindicated), with treatment goals aimed at clinical remission. Disease activity should be monitored every 1–3 months until the target is achieved. [4][14]10

Early Inflammatory Arthritis – Evidence‑Based Management

Referral & Diagnosis

The American College of Rheumatology (ACR) recommends urgent rheumatology referral within 6 weeks of symptom onset, immediate serologic work‑up (including anti‑CCP), and consideration of early disease‑modifying therapy within 3 months to prevent joint damage and preserve function【15】【16】.

Risk Stratification

A symptom duration of ≈ 2 weeks together with an elevated C‑reactive protein (CRP) identifies active inflammation and predicts a high risk of persistent/erosive disease【16】【17】【18】.
Presence of multiple swollen small joints, symmetric distribution, and raised acute‑phase reactants (CRP) place patients at high risk for persistent and erosive arthritis【16】【17】【18】.
Anti‑cyclic citrullinated peptide (anti‑CCP) positivity predicts erosive disease even when rheumatoid factor (RF) is negative【18】.

Laboratory & Imaging Assessment

Both erythrocyte sedimentation rate (ESR) and CRP should be measured; each independently predicts persistent arthritis【16】【17】【18】.
Baseline plain radiographs of both hands (PA and lateral) are advised to detect early erosive changes, which automatically classify the disease as persistent/erosive【18】.
When clinical examination is equivocal, power‑Doppler ultrasound of the hands can identify synovitis, effusion, and tenosynovitis【16】.
Clinical examination remains the primary diagnostic tool; imaging is used to confirm uncertain findings【16】.

Initial Symptomatic Management (First‑Line Pharmacotherapy)

Initiate non‑steroidal anti‑inflammatory drugs (NSAIDs) – e.g., naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily – for 4–6 weeks, using the lowest effective dose【16】【17】.
Prior to NSAID prescription, assess gastrointestinal, renal, and cardiovascular risk factors【16】【17】.
In patients with low blood pressure, NSAIDs may worsen hypotension and renal perfusion; start at lower doses and monitor blood pressure closely【16】.
If NSAIDs are ineffective or contraindicated, prescribe oral prednisone 10–20 mg daily for 2–4 weeks as bridge therapy【16】【17】.
Limit total systemic glucocorticoid exposure to < 6 months to reduce cumulative adverse effects【16】【17】.
Consider intra‑articular glucocorticoid injection into the most symptomatic proximal interphalangeal (PIP) joint for rapid localized relief【16】【17】.

DMARD Initiation (Disease‑Modifying Therapy)

When serology confirms high risk (positive RF or anti‑CCP, elevated ESR/CRP, multiple swollen joints), methotrexate should be started within 3 months of symptom onset【15】【16】【18】.
Methotrexate is the anchor DMARD and forms the core of the first treatment strategy unless contraindicated【15】【16】【17】.
Initiating DMARDs within the 3‑month “window of opportunity” prevents joint damage, improves long‑term outcomes, and reduces morbidity【18】.

Monitoring & Follow‑Up

Reassess joint symptoms, swelling, and pain weekly during the first month of therapy【16】【17】.
After DMARD initiation, disease activity should be evaluated every 1–3 months using tender/swollen joint counts, patient/physician global assessments, and ESR/CRP【16】【17】.
The therapeutic target is clinical remission; treatment should be adjusted until this goal is achieved【16】【17】.

Prognosis & Patient Education

Early DMARD therapy within 3 months is associated with significantly better outcomes regarding joint damage, physical function, and long‑term disability【15】【18】.
Without early intervention, patients face an increased risk of erosive disease, permanent joint deformity, and functional impairment【15】【18】.
Symptom relief often begins within weeks, but full disease control typically requires 3–6 months of DMARD therapy, and lifelong treatment may be necessary to maintain remission【16】【17】.

Pitfalls to Avoid

Do not postpone rheumatology referral while awaiting serologic results; the 6‑week referral window is critical【15】【16】.
A negative RF does not exclude inflammatory arthritis; seronegative disease is common early and anti‑CCP testing remains essential【18】.
NSAIDs can exacerbate renal hypoperfusion in hypotensive patients; monitor blood pressure and renal function closely【16】【17】.

Guideline Recommendations for Management of Synovitis

Initial Clinical Assessment & Risk Stratification

Elevated ESR or CRP independently predicts a persistent or erosive disease course, supporting early aggressive management. 19
A positive anti‑CCP antibody predicts erosive joint damage even when rheumatoid factor is negative, indicating high‑risk disease. 19
Baseline plain radiographs are recommended to detect early erosive changes; the presence of erosions classifies the disease as persistent/erosive. 19
Power‑Doppler ultrasound should be used when physical examination is equivocal to confirm synovitis, detect effusion, and assess tenosynovitis. 19

First‑Line Symptomatic Management

NSAID Therapy

Initiate NSAIDs for 4–6 weeks at the lowest effective dose (e.g., naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily). [20][21]
Assess gastrointestinal, renal, and cardiovascular risk factors before prescribing NSAIDs. [20][22]
NSAIDs are particularly indicated in patients with joint effusion or clinically overt synovitis. 20
NSAIDs should not be used as sole therapy for chronic persistent synovitis beyond 4 weeks; disease‑modifying treatment is required. [23][24]21

Glucocorticoid Therapy

If NSAIDs are ineffective or contraindicated, prescribe oral prednisone 10–20 mg daily for 2–4 weeks as bridge therapy. 21
Limit total systemic glucocorticoid exposure to less than 6 months to reduce cumulative adverse effects. 21
Perform intra‑articular glucocorticoid injection for mono‑ or oligo‑articular synovitis to achieve rapid localized relief. [25][22]
Avoid intra‑articular corticosteroid injection while awaiting response to oral antibiotics in Lyme arthritis. 26

Non‑Pharmacologic Measures

Apply ice or cool packs and recommend temporary rest for acute synovitis; evidence is extrapolated from acute gout management. [25][22]

Disease‑Modifying Therapy for Persistent Synovitis

Indications & Prognostic Factors

Initiate a conventional synthetic DMARD promptly in patients with polyarthritis (> 4 swollen joints) or oligoarthritis with poor‑prognostic factors (structural damage on radiographs, elevated ESR/CRP, dactylitis or nail involvement, positive RF or anti‑CCP, multiple swollen joints). [21][19]

Preferred DMARD Choice

Methotrexate is the preferred first‑line csDMARD, especially when skin involvement is present. Conditional recommendation based on larger effectiveness data and better long‑term safety compared with leflunomide or sulfasalazine. [21][27][23][24]
Subcutaneous methotrexate is conditionally recommended over oral methotrexate when feasible. [23][24]

Timing of Initiation

Start methotrexate within 3 months of symptom onset in high‑risk patients (“window of opportunity”) to prevent joint damage and improve long‑term outcomes. [19][27]
Do not delay rheumatology referral; arrange specialist follow‑up within 6 weeks of symptom onset. 19

Monitoring & Treatment Targets

Reassess disease activity every 1–3 months using tender/swollen joint counts, patient/physician global assessments, and ESR/CRP until the therapeutic target is reached. 27
The treatment target is clinical remission; if remission is not achieved within 6 months, modify the therapeutic regimen. 27
Patients who have not shown significant improvement by 3 months are unlikely to achieve the desired state later unless disease activity is reduced close to the target. 27

Special Etiologies

Calcium Pyrophosphate Deposition (CPPD)

For acute CPP crystal arthritis, joint aspiration and/or intra‑articular injection of a long‑acting glucocorticoid is commonly employed. [25][22]
Oral colchicine (0.5 mg up to 3–4 times daily) may be used, but renal impairment in older adults limits its tolerability. [25][22]

Lyme Arthritis

Treat with a 28‑day course of oral doxycycline, amoxicillin, or cefuroxime axetil. 26
If joint swelling persists or recurs after oral therapy, retreat with another 4‑week oral regimen or a 2–4‑week intravenous ceftriaxone course. 26
Delay re‑treatment for several months to allow for the expected slow resolution of inflammation. 26

Critical Pitfalls to Avoid

Do not dismiss inflammatory arthritis solely because rheumatoid factor is negative; anti‑CCP testing remains essential. 19
Do not postpone DMARD initiation in high‑risk patients; early treatment within 3 months prevents irreversible joint damage. [19][27]
Do not rely on NSAIDs as monotherapy for chronic synovitis beyond 4–6 weeks; disease‑modifying therapy is required. [23][21]24
Do not prescribe chronic low‑dose glucocorticoids due to the risk of cumulative adverse effects. 21

Diagnostic Workup for Inflammatory Arthritis of the Hand

Initial Clinical and Laboratory Assessment

The American College of Radiology (ACR) recommends that the first evaluation include plain postero‑anterior and lateral radiographs of both hands together with baseline laboratory testing (ESR, CRP, rheumatoid factor, anti‑CCP antibodies, and ANA) to risk‑stratify for inflammatory arthritis. 28
The presence of dactylitis, nail pitting, onycholysis, or extensor‑surface psoriatic plaques on physical examination strongly suggests psoriatic arthritis. 29
Symmetric involvement of the metacarpophalangeal, proximal interphalangeal joints and wrists is characteristic of rheumatoid arthritis. 28
Elevated ESR or CRP independently predicts a persistent or erosive disease course and should guide the intensity of early therapy (moderate‑quality evidence). 30
Positive anti‑CCP antibodies predict erosive disease even when rheumatoid factor is negative; seronegative disease is common in early rheumatoid arthritis (moderate‑quality evidence). 30

Excluding Septic Arthritis

In patients with fever, erythema, warmth, severe pain, or a mono‑articular presentation, immediate joint aspiration is required before any advanced imaging to rule out septic arthritis. 31
Aspirated synovial fluid must be sent for cell count with differential, Gram stain, bacterial culture, and crystal analysis to exclude infection, gout, or pseudogout. 31
Aspiration should not be delayed for imaging; it can be performed without guidance if the joint is distended, or with fluoroscopy/ultrasound when needed. 31

Imaging Strategy

First‑Line: Plain Radiography

Baseline PA and lateral hand radiographs detect early erosive changes, peri‑articular osteopenia, and uniform joint‑space narrowing (ACR recommendation). 28
Radiographs have a specificity of 100 % but a sensitivity of only ≈ 19 % for erosions compared with CT; despite low sensitivity they remain the recommended initial imaging modality. 28

Second‑Line: Power‑Doppler Ultrasound

When clinical findings are equivocal or radiographs are normal but suspicion remains high, power‑Doppler ultrasound of the hands and wrists should be performed to confirm synovitis, joint effusion, and tenosynovitis (ACR recommendation). 32
Ultrasound outperforms physical examination in detecting synovitis and structural damage; power‑Doppler signal identifies active inflammation and predicts subsequent erosion progression (moderate‑quality evidence). 32
High‑resolution ultrasound can visualize small dorsal and volar bone erosions, though it is less sensitive for erosions on the radial/ulnar aspects of the carpal bones. 32
In early rheumatoid arthritis that does not meet the 2010 ACR/EULAR classification criteria, the addition of power‑Doppler synovitis improves diagnostic accuracy (AUC 0.905 → 0.962). 30
Ultrasound also demonstrates characteristic tophi in gout and chondrocalcinosis in pseudogout, aiding differential diagnosis. 33

Third‑Line: Magnetic Resonance Imaging (MRI)

MRI (with intravenous gadolinium) is reserved for cases where ultrasound is unavailable, the diagnosis remains uncertain after ultrasound, or when assessment of bone‑marrow edema is required as a prognostic marker (ACR recommendation). 32
MRI is more sensitive than ultrasound for early rheumatoid arthritis and provides superior detection of synovitis, tenosynovitis, and bone‑marrow edema (moderate‑quality evidence). 33
Bone‑marrow edema on MRI is the strongest independent predictor of future radiographic erosion progression (coefficient 0.75–0.82, p < 0.001). 30
Unlike ultrasound, MRI uniquely visualizes bone‑marrow changes, which are the most powerful prognosticators for disease progression in rheumatoid arthritis. 32

Imaging Modalities Not Recommended

Computed tomography, bone scintigraphy, MR or CT arthrography, and conventional arthrography do not add diagnostic or therapeutic value for suspected inflammatory arthritis and should not be ordered (ACR recommendation). 32

Referral and Management Timing

The American College of Rheumatology (ACR) advises arranging rheumatology follow‑up within 6 weeks of symptom onset; referral should not be delayed while awaiting serologic results (moderate‑quality evidence). 30

Common Pitfalls to Avoid

Do not rely on a negative rheumatoid factor to exclude rheumatoid arthritis; seronegative disease is frequent early, and anti‑CCP testing remains essential. 28
Do not postpone joint aspiration for advanced imaging when septic arthritis is suspected; timely aspiration is critical. 31
Do not consider a normal radiograph sufficient to rule out inflammatory arthritis, given its low (≈ 19 %) sensitivity for early erosions. 28

Early Assessment and Management of Chronic Small‑Joint Arthritis

Clinical Definition and Initial Evaluation

In patients presenting with joint swelling, a symptom duration of ≥ 6 weeks together with pain or stiffness defines true arthritis and helps differentiate it from cellulitis, bursitis, or soft‑tissue infection. 34, 35
Early‑morning stiffness, symmetric involvement of small joints, and constitutional symptoms (fatigue, low‑grade fever, weight loss) are characteristic of rheumatoid arthritis. 34, 36
A 28‑joint count (bilateral PIP 1‑5, MCP 1‑5, wrists, elbows, shoulders, knees) is used to quantify disease activity in inflammatory arthritis. 34, 36
Physical signs of redness, warmth, or joint effusion confirm active synovitis. 37
Symmetric polyarticular small‑joint disease points toward rheumatoid arthritis, whereas asymmetric oligoarthritis with DIP involvement suggests psoriatic arthritis or osteoarthritis. 37

Laboratory Markers

Elevated ESR and CRP independently predict a persistent or erosive disease course and should guide the intensity of early therapy. 34, 36
Positive rheumatoid factor (RF) and anti‑CCP antibodies predict erosive disease; anti‑CCP positivity remains a strong predictor even when RF is negative. 34, 35, 36

Imaging Strategy

Baseline postero‑anterior and lateral radiographs of both hands and wrists detect early erosive changes, peri‑articular osteopenia, and uniform joint‑space narrowing. Radiographs have 100 % specificity but only ≈ 19 % sensitivity for erosions, so a normal film does not exclude inflammatory arthritis. 34, 35, 36
When clinical examination is equivocal or radiographs are normal, power‑Doppler ultrasound of the hands and wrists should be performed to confirm synovitis, effusion, and tenosynovitis; it outperforms physical exam and predicts subsequent erosion progression. 38
MRI with intravenous gadolinium is reserved for cases where ultrasound is unavailable or diagnosis remains uncertain; the presence of bone‑marrow edema on MRI is the strongest independent predictor of future radiographic erosion progression. 38
CT, bone scintigraphy, MR/CT arthrography, and conventional arthrography are not recommended for the work‑up of suspected inflammatory arthritis. 38

Pharmacologic Management

NSAIDs should be started at the lowest effective dose for 4–6 weeks (e.g., naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily) after assessing gastrointestinal, renal, and cardiovascular risk factors. 37
If NSAIDs are ineffective or contraindicated, a bridge course of oral prednisone 10–20 mg daily for 2–4 weeks is recommended; total systemic glucocorticoid exposure should be limited to < 6 months to reduce cumulative toxicity. 37
Intra‑articular glucocorticoid injection into the most symptomatic joint provides rapid localized relief. 37
Chronic low‑dose glucocorticoid therapy is strongly discouraged because of long‑term adverse effects. 37

Referral, Follow‑up, and Therapeutic Targets

Rheumatology follow‑up should be arranged within 6 weeks of symptom onset; referral must not be delayed while awaiting serologic results. 34, 36
Patients with ≥ 1 swollen small joint, symptom duration ≥ 6 weeks, and positive RF or anti‑CCP should be seen urgently. 34, 35
Establish early arthritis clinics that can provide urgent appointments within 1–2 weeks for suspected early rheumatoid arthritis. 34, 36
The therapeutic target is clinical remission; disease activity should be reassessed every 1–3 months using tender/swollen joint counts, patient/physician global assessments, and ESR/CRP. 34

Comprehensive Pain Assessment

Pain evaluation should incorporate:
- Physical disability (activities of daily living, social participation, fitness, pain‑related fear).
- Psychological factors (catastrophizing, fear of movement, self‑efficacy, distress).
- Social factors (family reactions, work status, economic concerns, housing).
- Sleep quality (duration, restorative feeling, hygiene).
- Obesity and other health risks (smoking, alcohol use).
- (All components supported by evidence). 37

Non‑Pharmacologic Interventions

All patients with inflammatory arthritis should be referred to a structured exercise program supervised by a subspecialist. 39
Weight management has demonstrated positive effects on rheumatoid arthritis outcomes (moderate‑quality evidence). 37
Cognitive‑behavioral therapy for insomnia improves both sleep quality and pain in osteoarthritis patients (moderate‑quality evidence). 37

Early Rheumatoid Arthritis: Urgent Referral and Early Disease‑Modifying Therapy

Clinical Features Suggestive of Inflammatory Arthritis

Morning stiffness lasting ≥ 30 minutes (often > 1 hour) strongly favors rheumatoid arthritis over osteoarthritis in adults ≥ 50 years old【40】.
Even when joint swelling is not visible, patients may report achy pain; ultrasound frequently detects synovitis in such cases, confirming active inflammation【40】.
A positive family history of rheumatoid arthritis increases genetic susceptibility, although it is not required for diagnosis【41】.

Immediate Diagnostic Workup

Laboratory Tests

Elevated ESR or CRP independently predicts a persistent or erosive disease course and should guide the intensity of early treatment【42】【40】.
Testing for rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies is essential; anti‑CCP positivity predicts erosive disease even when RF is negative, while seronegative disease is common in early rheumatoid arthritis【42】【40】.
Antinuclear antibody (ANA) screening helps exclude other connective‑tissue diseases【40】.
Baseline urinalysis and liver‑function tests are recommended before initiating disease‑modifying antirheumatic drugs (DMARDs)【40】.

Imaging

Power‑Doppler ultrasound of the hands and wrists should be performed when physical examination is equivocal or radiographs are normal; it confirms synovitis, joint effusion, and tenosynovitis, and predicts subsequent erosion progression【40】.

Risk Stratification for Persistent/Erosive Disease

Presence of multiple swollen small joints (e.g., bilateral metacarpophalangeal and proximal interphalangeal joints) places patients at high risk for persistent and erosive arthritis【42】【40】.
Prolonged morning stiffness (≈ 3 hours) and symptom duration of ≥ 3 months indicate active, established inflammation and increase risk of chronic disease【40】.
Positive RF or anti‑CCP antibodies, especially anti‑CCP, are the strongest predictors of future erosive joint damage【42】【40】.

Immediate Symptomatic Management

NSAID Therapy

Initiate naproxen 500 mg twice daily or meloxicam 7.5–15 mg once daily for 4–6 weeks at the lowest effective dose, after assessing gastrointestinal, renal, and cardiovascular risk factors【42】【43】.
NSAIDs provide symptomatic relief but do not prevent joint damage; they should not be used as sole therapy beyond 4–6 weeks【42】.

Glucocorticoid Bridge Therapy

If NSAIDs are ineffective or contraindicated, prescribe oral prednisone 10–20 mg daily for 2–4 weeks as a bridge to DMARDs【42】.
Limit total systemic glucocorticoid exposure to < 6 months to reduce cumulative adverse effects【42】.
Consider intra‑articular glucocorticoid injection into the most symptomatic proximal interphalangeal joint for rapid localized relief【42】.
Chronic low‑dose glucocorticoid therapy is strongly discouraged because of long‑term toxicity【42】.

Urgent Rheumatology Referral and Early DMARD Initiation

Arrange rheumatology follow‑up within 6 weeks of symptom onset; referral must not be delayed while awaiting serologic results【42】【40】.
Start methotrexate (the anchor DMARD) within 3 months of symptom onset in patients with high‑risk features (multiple swollen small joints, elevated ESR/CRP, positive RF or anti‑CCP)【42】【40】.
Initiating DMARD therapy within the “window of opportunity” (first 3 months) prevents irreversible joint damage, improves long‑term outcomes, and reduces morbidity【42】【40】.

Monitoring and Therapeutic Targets

Reassess disease activity every 1–3 months using tender/swollen joint counts, patient/physician global assessments, and ESR/CRP until the therapeutic target is reached【42】.
The therapeutic target is clinical remission; if remission is not achieved within 6 months, modify the treatment regimen accordingly【42】.

Critical Pitfalls to Avoid

Do not postpone rheumatology referral while awaiting serologic results; the 6‑week window is critical for early disease‑modifying therapy【42】【40】.
Do not dismiss inflammatory arthritis solely because RF is negative; seronegative disease is common early, and anti‑CCP testing remains essential【42】【40】.
Do not rely on NSAIDs as monotherapy for chronic synovitis beyond 4–6 weeks; disease‑modifying therapy is required【42】.
Do not delay DMARD initiation in high‑risk patients; early treatment within 3 months prevents irreversible joint damage【42】【40】.

Prognosis and Patient Education

Early DMARD therapy initiated within 3 months is associated with significantly better outcomes regarding joint damage, physical function, and long‑term disability【42】【40】.
Without early intervention, patients face an increased risk of erosive disease, permanent joint deformity, and functional impairment【42】.